A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Recruiting · NCT03193892 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking Union Medical College Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
Who can take part
Age range
No age limits stated
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Gender: female.
- Age: no limitation.
- Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the patient.
Exclusion criteria
- Suspected LAM patients without other supporting evidence for LAM diagnosis.
- No diffuse cystic lesions in the lung.
- Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established.
- Without signed informed consent.
- Difficult to follow up.
Where it is running
1 location listed.
- Peking Union Medical College Hospital - Beijing, Beijing Municipality, China